SCHEMBL3011309

SCHEMBL3011309

Cc1cc(C)cc(Cc2csc(N3CCN(S(=O)(=O)c4ccccc4Cl)CC3)n2)c1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 7/20 0.43
MEN1 O00255 2/20 0.43
LMNA P02545 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPK1 P28482 1/20 0.43
MAPT P10636 2/20 0.42
ALDH1A1 P00352 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
GBA1 P04062 2/20 0.41
FAAH O00519 1/20 0.40
EPHX2 P34913 1/20 0.40
TP53 P04637 1/20 0.40
CHRM2 P08172 1/20 0.39
CHRM5 P08912 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
PIK3CA P42336 1/20 0.38
MTOR P42345 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3005306 0.92 TSHR (0.43) MEN1LMNAKMT2AMAPK1MAPT
SCHEMBL3010327 0.92 MEN1 (0.43) CHRM4MEN1LMNAKMT2AMAPK1
SCHEMBL2999775 0.91 FAAH (0.45) CHRM4MEN1LMNAKMT2AMAPK1
SCHEMBL3008268 0.90 CHRM4 (0.45) CHRM4MEN1LMNAKMT2AMAPK1
SCHEMBL3014938 0.89 CHRM4 (0.43) CHRM4MEN1LMNAKMT2AMAPK1
SCHEMBL3006655 0.89 MAPT (0.45) LMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL3001890 0.89 GBA1 (0.42) MEN1LMNAKMT2AMAPK1MAPT
SCHEMBL3018571 0.89 TRPV4 (0.45) MEN1LMNAKMT2AMAPK1MAPT
SCHEMBL3012898 0.89 CHRM4 (0.47) CHRM4MEN1LMNAKMT2AMAPK1
SCHEMBL3016519 0.88 MAPT (0.43) CHRM4MEN1LMNAKMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CHRM4 4476/4885MEN1 454/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.